Crohnology

Cover Block

From the public record

Attribute	Details
Name	Crohnology (by Healthy Labs)
Tagline	A patient-reported health-tracking network for individuals with Crohn's disease and ulcerative colitis.
Headquarters	San Francisco, CA, US
Founded	2011
Stage	Seed
Business Model	B2C
Industry	Healthtech
Technology	Software (Non-AI)
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed (total disclosed ~$350,000)

Links

From the public record

• Website: https://crohnology.net/
• Y Combinator Company Profile: https://www.ycombinator.com/companies/crohnology-by-healthy-labs
• Facebook: https://www.facebook.com/Crohnology/

The Short Version

From the public record Crohnology built a patient-reported health-tracking network for individuals with Crohn's disease and ulcerative colitis, a venture that remains noteworthy for its early focus on patient-generated real-world data as a research asset rather than a simple symptom tracker [Y Combinator, July 2026 page update]. Founded in 2011 by Will Cole, a functional medicine practitioner, and Sean Ahrens, a technical founder with a personal connection to the disease, the company participated in Y Combinator's Summer 2012 batch [MedCity News, January 2012][Y Combinator, July 2026 page update]. Its core proposition was to turn patients into contributors of structured health data, positioning itself with the motto "We turn Patients into Researchers" and reporting a network of over 27,000 patients [Y Combinator, July 2026 page update][Altss, retrieved 2026]. The founding team combined clinical insight from Cole with Ahrens's software development and startup experience, including a prior YC-funded venture [ExpertFile, retrieved 2026][Dr. Will Cole, retrieved 2026]. The company's disclosed funding was modest, totaling approximately $350,000 from a combination of Y Combinator and associated sources, with no subsequent institutional rounds confirmed [DrChrono, February 2022][aVenture Company Research, retrieved 2026]. For investors, the primary watch points over the next 12-18 months would involve clarifying the current operational status of the network under Healthy Labs, validating the commercial model for its patient data, and assessing whether the early community traction can be translated into a sustainable business.

Single-source, plausible -- Core company facts are corroborated by multiple sources, but key operational metrics and recent developments rely on company-directory entries or dated interviews.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Growth Profile	Venture Scale
Founding Team	Solo Founder

The Company in Brief

From the public record

Crohnology was founded in 2011 to build a patient-centric data network for inflammatory bowel disease (IBD), a bet that patient-reported outcomes could generate valuable real-world evidence [Y Combinator]. The founding team, Will Cole and Sean Ahrens, brought a blend of clinical and technical perspectives; Cole is a functional medicine practitioner focused on autoimmune conditions, while Ahrens, diagnosed with Crohn's disease at age 12, provided the technical and patient experience [Dr. Will Cole] [The Doctor's Channel]. The company incorporated in San Francisco and was accepted into Y Combinator's Summer 2012 batch, a key early milestone that provided initial capital and structure [Y Combinator] [DrChrono, February 2022].

A reported $164,000 in funding was secured around January 2012, which, combined with capital from the accelerator, brought the total raised at that stage to approximately $150,000 [aVenture Company Research] [DrChrono, February 2022]. The company's core development phase and beta launch occurred in early 2012, positioning it as a "social healthcare project" and an online symptom-tracking network for the IBD community [MedCity News, January 2012] [IBD BIOM]. Its primary traction signal was the growth of its patient network, which it later reported had surpassed 27,000 individuals with Crohn's disease or ulcerative colitis [Y Combinator] [Altss].

The company's later operational history is less clear from public records. The Y Combinator profile lists it as being "by Healthy Labs," suggesting a possible acquisition or operational handoff, though the terms and timing are not disclosed [Y Combinator]. As of the most recent available data, the company was listed with one employee, and no current open roles or active hiring campaigns are visible on public career pages [Y Combinator].

Single-source, plausible -- Key founding and funding details are corroborated by multiple sources, but later-stage operational status and the patient network figure rely on single-source company profiles.

What They Have Built

Mixed sourcing The product is a patient-reported health-tracking network, a concept that predates much of the current digital health landscape. Crohnology was built not as a passive symptom diary but as a structured data collection platform with a social layer, positioning itself with the tagline "We turn Patients into Researchers" [Y Combinator, July 2026 page update]. Its core function was to provide a private symptom tracker for individuals with Crohn's disease, ulcerative colitis, and related gastrointestinal conditions, facilitating both personal health monitoring and community information sharing [Crohnology.net, retrieved 2026] [Crunchbase, retrieved 2026].

The available public descriptions frame it as a "global online symptom and health tracking network" and a "social healthcare project," suggesting a web-based platform where patients could log symptoms and treatments while connecting with others [Y Combinator, July 2026 page update] [IBD BIOM, retrieved 2026]. The company's reported collaborations with research institutions like the University of North Carolina and the Crohn's & Colitis Foundation of America indicate the platform was designed to aggregate and structure patient-reported data for research purposes, though the specific data-sharing mechanisms and consent frameworks are not detailed in public sources [Y Combinator, July 2026 page update]. No public announcements detail a specific technology stack, a roadmap for future features, or a transition to a mobile-first application.

From the public record The market for patient-generated health data platforms is gaining attention not for its immediate size but for its potential to address the chronic data gaps in complex, heterogeneous conditions like inflammatory bowel disease (IBD).

No third-party TAM, SAM, or SOM analysis was identified specifically for patient-reported outcome (PRO) networks in the IBD space. The available sizing context comes from the patient population itself. In the United States, the Crohn's & Colitis Foundation states that IBD affects nearly one in 100 people, a figure that translates to a domestic patient population of over 3 million individuals [Crohn's & Colitis Foundation]. This represents the core addressable user base for a symptom-tracking network. For comparison, the broader digital therapeutics market for chronic disease management was valued at $5.3 billion globally in 2022, with projections to reach $17.7 billion by 2027, according to a report cited by Grand View Research [Grand View Research, 2023]. Crohnology's model, focused on data aggregation for research, operates in a narrower but analogous segment within this larger landscape.

Demand drivers for such a platform are anchored in the specific challenges of managing Crohn's disease and ulcerative colitis. These are lifelong conditions with symptoms that fluctuate unpredictably, making consistent tracking between clinical visits valuable for both patient self-management and clinical research [Crohn's & Colitis Foundation]. A significant tailwind is the growing emphasis on real-world evidence (RWE) by pharmaceutical companies and regulatory bodies. The cited research collaborations with entities like Genentech and Qu Biologics suggest an early recognition of this network's utility for observational studies and patient recruitment [Y Combinator, July 2026 page update]. Furthermore, patient advocacy groups, led by the non-profit Crohn's & Colitis Foundation, actively work to improve quality of life and accelerate product development, creating a supportive ecosystem for patient-centric tools [Crohn's & Colitis Foundation].

Adjacent and substitute markets present both competition and potential expansion paths. The primary substitute is the traditional method of data collection: paper diaries and infrequent clinic-based assessments, which are prone to recall bias and low compliance. More direct adjacent markets include general-purpose health tracking apps (e.g., Apple Health, MyFitnessPal) and electronic patient-reported outcome (ePRO) systems used in clinical trials by companies like Medidata. The key differentiator for a condition-specific network is the structured, disease-relevant data schema and the built-in community of peers, which general tools lack. Regulatory forces are generally favorable but introduce complexity. The 21st Century Cures Act in the U.S. has encouraged the use of RWE and patient-generated data. However, platforms aggregating health information for research must navigate HIPAA compliance, data de-identification standards, and, if seeking regulatory approval as a software-as-a-medical-device (SaMD), more stringent FDA pathways.

Metric	Value
U.S. IBD Patient Population	3.1 million patients
Global Digital Therapeutics Market (2022)	5.3 $B
Projected Digital Therapeutics Market (2027)	17.7 $B

The available numbers illustrate the scale of the underlying condition and the rapidly growing digital health category it sits within. The multi-billion-dollar digital therapeutics forecast underscores investor interest in software-based chronic disease management, though Crohnology's research-data model represents a more specialized and earlier-stage wedge.

Single-source, plausible -- Market sizing relies on a patient population figure from a leading disease foundation and an analogous market report from a third-party research firm. The company's specific market segment and commercial model are not independently sized.

Who Else Is Fighting for This

Mixed sourcing Crohnology's position is defined by its early focus on a specific chronic condition, creating a patient-reported data network that sits between general wellness trackers and formal clinical research platforms.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Crohnology	Patient-reported health-tracking network for IBD	Seed (~$350k disclosed); YC S12	Proprietary dataset from >27k IBD patients; research collaborations with academic/medical institutions	[Y Combinator, July 2026], [DrChrono, February 2022]
Curebase	Decentralized clinical trial platform	Series B ($70M total)	Enables remote trial participation; targets sponsors/CROs, not patients directly	[Crunchbase]
Juno	Patient community for clinical trial matching	Seed ($3.5M)	Focus on connecting patients to trials; less emphasis on longitudinal symptom tracking	[Crunchbase]
HealthKey	Digital health wallet and patient data platform	Unknown	Broader patient data aggregation across conditions; interoperability focus	[Crunchbase]
Panoptive	Real-world evidence platform for life sciences	Seed ($2.5M)	Aggregates data from EHRs and wearables for pharma analytics	[Crunchbase]

The competitive map for patient-centric health data splits into three segments. Incumbent patient communities are dominated by non-profit foundations, most notably the Crohn's & Colitis Foundation, which provides disease information and support but does not structure patient data for research [Crohn's & Colitis Foundation]. Challengers include decentralized trial platforms like Curebase, which facilitate research but typically treat patients as trial subjects rather than ongoing data contributors. Adjacent substitutes are general health tracking apps and electronic health record portals, which capture data but lack the disease-specific community and research-grade structuring that defines Crohnology's niche.

Crohnology's defensible edge today is its concentrated, consented dataset from over 27,000 individuals with inflammatory bowel disease [Y Combinator, July 2026]. This asset is durable in the near term because network effects in a rare disease population create high switching costs; patients who have contributed years of personal health history are unlikely to migrate en masse. The edge is perishable, however, if a better-capitalized competitor acquires a similar cohort through partnerships with large provider networks or patient advocacy groups, effectively commoditizing the data asset.

The company is most exposed on two fronts. First, it lacks the capital and commercial infrastructure of platforms like Curebase or Panoptive, which are built to serve pharmaceutical and clinical research organizations with turnkey analytics and compliance tools [Crunchbase]. Second, its reliance on a purely patient-reported model leaves it vulnerable to platforms that integrate objective data streams from connected devices and electronic health records, offering a more complete picture preferred by research sponsors.

The most plausible 18-month scenario hinges on the monetization of its patient network. If Crohnology can formalize and scale its research collaboration model into a recurring revenue stream with life sciences partners, it becomes an attractive niche asset, potentially a winner in the specialized real-world evidence segment. If it fails to convert its community into sustainable commercial contracts, it becomes a loser in the capital-intensive healthtech landscape, likely superseded by platforms that secure later-stage funding to build more comprehensive, multi-condition data ecosystems.

Single-source, plausible -- Competitor data sourced from Crunchbase; subject's positioning and scale claims are from the company's Y Combinator profile and a founder interview.

Opportunity

From the public record The opportunity for Crohnology is to become the definitive, patient-owned real-world data platform for inflammatory bowel disease, a role that could command a premium from pharmaceutical developers and health systems if its network reaches critical mass.

The headline opportunity is the creation of a patient-centric research utility, a platform that could systematically lower the cost and time of clinical development for new IBD therapies. The company’s early positioning, “We turn Patients into Researchers,” frames a direct path to this outcome [Y Combinator, July 2026 page update]. Unlike traditional data brokers or research registries, a patient-controlled network that aggregates longitudinal symptom and treatment data could become the default source for observational studies and patient recruitment. The cited collaborations with entities like the University of North Carolina and Genentech suggest this utility was recognized, even in early stages, by credible research organizations [Y Combinator, July 2026 page update]. For a company that reported a network of over 27,000 patients, the reachable outcome is not merely a supportive community but a category-defining data asset.

Growth from that early foundation could follow several concrete paths. The scenarios below outline how the company could scale its impact and commercial footprint.

Scenario	What happens	Catalyst	Why it's plausible
Research Platform Standard	Academic and biopharma researchers adopt the network as a primary source for patient-reported outcomes (PRO) data and cohort identification.	A landmark publication co-authored with a major research institution validates the platform's data quality and leads to a formal partnership with a pharmaceutical company.	Early research collaborations demonstrate institutional interest [Y Combinator]. Patient networks are increasingly valued for real-world evidence generation in chronic diseases.
Foundation-Led Scale	The Crohn's & Colitis Foundation formally integrates the platform into its patient support and research infrastructure, driving nationwide patient adoption.	The Foundation's IBD Ventures funding program or its corporate partnership pathway selects the platform for a multi-year initiative [Crohn's & Colitis Foundation].	The Foundation's mission aligns with patient empowerment and accelerating product development [Crohn's & Colitis Foundation]. Crohnology was already listed as a collaborator [Y Combinator].

Compounding for a network like this is classic: each additional patient improves the dataset's statistical power and demographic diversity, making it more valuable to researchers. Each successful research partnership serves as a credibility signal that attracts more patients, creating a two-sided network effect. The data itself forms a moat; longitudinal, patient-consented health data is difficult and expensive to replicate. The early evidence of a 27,000-patient network, while unverified by independent sources, suggests the initial steps of this flywheel were attempted [Y Combinator, Altss].

The size of the win, should the Research Platform Standard scenario play out, can be framed by comparable assets. Platforms specializing in real-world data and patient recruitment have attracted significant value. For example, the 2021 acquisition of TriNetX, a healthcare real-world data network, by a private equity consortium was reported at a valuation exceeding $1 billion [Reuters, 2021]. While Crohnology’s focus is specific to IBD, a dominant position in a high-need therapeutic area with a chronic, lifelong patient population could support a specialized but valuable platform. If the network achieved deep penetration within the estimated 3 million+ U.S. IBD patient population and monetized data access and recruitment services, a valuation in the high hundreds of millions is a plausible upper-bound outcome (scenario, not a forecast).

Single-source, plausible -- The core opportunity thesis relies on the company's stated positioning and early collaborations, which are cited from its Y Combinator profile. The patient network size is reported by the company and one aggregator but lacks independent verification. The scenario plausibility is supported by the cited collaborations and the well-documented market need for real-world evidence in biopharma.

Sources

From the public record

1. [Y Combinator, July 2026 page update] Crohnology (by Healthy Labs): We turn Patients into Researchers. | https://www.ycombinator.com/companies/crohnology-by-healthy-labs

2. [Altss, retrieved 2026] Crohnology (by Healthy Labs) , YC Company Profile | https://altss.com/companies/yc/crohnology-by-healthy-labs

3. [MedCity News, January 2012] Crohnology aims to connect people with Crohn’s disease and Colitis | https://medcitynews.com/2012/01/crohnology-aims-to-connect-people-with-crohns-disease-and-colitis/

4. [DrChrono, February 2022] On the Health Record: Conversation with DrChrono’s VP of Product, Sean Ahrens | https://m.drchrono.com/blog/2022/02/on-the-health-record-conversation-with-drchronos-vp-of-product-sean-ahrens/

5. [aVenture Company Research, retrieved 2026] Crohnology (by Healthy Labs) - aVenture Company Research | https://aventure.vc/companies/crohnology-by-healthy-labs-san-francisco-ca-us

6. [The Doctor's Channel, retrieved 2026] Crohnology: Bringing Together a World of Crohn’s Patients - The Doctor's Channel | https://www.thedoctorschannel.com/view/crohnology-bringing-together-a-world-of-crohns-patients/

7. [Dr. Will Cole, retrieved 2026] About Dr. Will Cole | https://drwillcole.com/about/

8. [ExpertFile, retrieved 2026] Sean Ahrens Profile | https://expertfile.com/experts/sean.ahrens

9. [Crohnology.net, retrieved 2026] CrohnOlogy | https://crohnology.net/

10. [IBD BIOM, retrieved 2026] IBD BIOM | Inflammatory Bowel Disease Biomarkers Programme. | http://www.ibdbiom.eu/

11. [Crunchbase, retrieved 2026] Crohnology Company Profile | https://www.crunchbase.com/organization/crohnology

12. [Crohn's & Colitis Foundation] Our Mission and Core Values | https://www.crohnscolitisfoundation.org/about/mission

13. [Grand View Research, 2023] Digital Therapeutics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/digital-therapeutics-market

14. [Reuters, 2021] TriNetX to be acquired by private equity firms in deal valuing co at over $1 bln | https://www.reuters.com/article/healthcare-trinetx-m-a-idUSL4N2LQ2VY/